Categories Earnings, Technology

Wall Street expects 9% growth in Infosys Q2 revenue

Information technology firm Infosys Limited (NYSE: INFY) is slated to report second-quarter 2020 earnings results on Friday, October 11, before the opening bell. Despite the concerns relating to the slowing economy in different parts of the world, Wall Street expects the company to report a 9% jump in revenues to $3.19 billion during the quarter.

The Bengaluru-headquartered firm is projected to report second-quarter earnings of $0.14 per share, a cent higher than what it reported last year.

Analysts have hit bulls-eye in predicting the bottom-line results of Infosys in three of the past four quarters. In just one quarter, Infosys missed the average market estimate by a cent.  

Infosys Q1 profit rises 2%

Stagnation in economic growth in China and Europe, as well as the lack of clarity relating to Brexit are expected to dent the second-quarter results. In fact, Infosys recently acquired Irish contact center Eishtec for an undisclosed amount, in a move that could be seen as setting up of an operating hub outside UK.

Infosys had also earlier this year bought a 75% stake in ABN AMRO unit Stater to add fillip to its US mortgage business.

READ: NYU professor who predicted Amazon-Whole Foods deal forecasts death of Tesla, 4 others

During the first quarter of 2020, Infosys reported a 2% increase in earnings helped by higher revenues as well as lower income tax expenses. The company also lifted revenue growth outlook for fiscal 2020 that is above the Street view.

Segment growth was robust with all large regions and most verticals growing at double digits year-over-year in constant currency.

INFY stock has gained 18% in the year-to-date period. The stock has a 12-month average price target of $12.75, which is at a 14% upside from Wednesday’s trading price.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top